Investigational drug · Phase 3
SYHX1901
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate to Severe Plaque Psoriasis, Severe Alopecia Areata.
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 3, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "SYHX1901"
First trial start
2025
May 26, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYHX1901", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Plaque Psoriasis
- Severe Alopecia Areata
Approved drugs for the same conditions: Plaque psoriasis · Alopecia areata · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "SYHX1901" as an intervention, largest first.
- A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque PsoriasisPivotal-lookingNot yet recruiting
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT06943950 · 500 participants (planned) · Start Jun 1, 2025 · Primary completion Apr 28, 2027
Drug: SYHX1901 · For: Moderate to Severe Plaque Psoriasis
- Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata PatientsPivotal-lookingNot yet recruiting
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT06562894 · 156 participants (planned) · Start May 26, 2025 · Primary completion May 31, 2027
Drug: SYHX1901; Placebo · For: Severe Alopecia Areata
- A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo PatientsPivotal-lookingStatus unknown
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT06511739 · 144 participants (planned) · Start May 27, 2024 · Primary completion Aug 1, 2025
Drug: SYHX1901; placebo · For: Non-segmental Vitiligo
Sites: Shijiazhuang, China
- The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy SubjectsPivotal-lookingStatus unknown
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT04880512 · 102 participants (planned) · Start May 31, 2021 · Primary completion Aug 20, 2022
Drug: SYHX 1901 tablets; Placebo · For: Healthy Subjects
Sites: Shanghai, China
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT05858047 · 93 participants · Start Apr 11, 2023 · Primary completion Feb 21, 2024
Drug: Placebo; SYHX1901 · For: Effects, Drug Side
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- SYHX1901, an oral dual Janus kinase and spleen tyrosine kinase inhibitor, for moderate-to-severe plaque psoriasis: A randomized phase 2 trial.
Han L, Zhu L, Yu G, et al. · J Am Acad Dermatol 2026
Also in development for Moderate to Severe Plaque Psoriasis
- CMS-D001Phase 32 trials
Dermavon Holdings Limited · Moderate to Severe Plaque Psoriasis, Moderate to Severe Atopic Dermatitis
- WD-890Phase 32 trials
Zhejiang Wenda Pharma Technology LTD. · Brief Description of Focus of Study, Moderate to Severe Plaque Psoriasis
- SHR-1139Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Moderate to Severe Plaque Psoriasis, Palmoplantar Pustulosis of Adults, Pyoderma Gangrenosum
- HS-20118Phase 21 trial
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.